Literature DB >> 33649193

Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.

Jong Hyuk Kim1,2,3,4, Kate Megquier5, Rachael Thomas6, Aaron L Sarver7,3,8, Jung Min Song3, Yoon Tae Kim9, Nuojin Cheng10, Ashley J Schulte7,2,3, Michael A Linden7,3,11, Paari Murugan7,3,11, LeAnn Oseth3, Colleen L Forster12, Ingegerd Elvers5,13, Ross Swofford5, Jason Turner-Maier5, Elinor K Karlsson5,14, Matthew Breen6,15, Kerstin Lindblad-Toh5,13, Jaime F Modiano7,2,3,4,11,16,17.   

Abstract

Sporadic angiosarcomas are aggressive vascular sarcomas whose rarity and genomic complexity present significant obstacles in deciphering the pathogenic significance of individual genetic alterations. Numerous fusion genes have been identified across multiple types of cancers, but their existence and significance remain unclear in sporadic angiosarcomas. In this study, we leveraged RNA-sequencing data from 13 human angiosarcomas and 76 spontaneous canine hemangiosarcomas to identify fusion genes associated with spontaneous vascular malignancies. Ten novel protein-coding fusion genes, including TEX2-PECAM1 and ATP8A2-FLT1, were identified in seven of the 13 human tumors, with two tumors showing mutations of TP53. HRAS and NRAS mutations were found in angiosarcomas without fusions or TP53 mutations. We found 15 novel protein-coding fusion genes including MYO16-PTK2, GABRA3-FLT1, and AKT3-XPNPEP1 in 11 of the 76 canine hemangiosarcomas; these fusion genes were seen exclusively in tumors of the angiogenic molecular subtype that contained recurrent mutations in TP53, PIK3CA, PIK3R1, and NRAS. In particular, fusion genes and mutations of TP53 cooccurred in tumors with higher frequency than expected by random chance, and they enriched gene signatures predicting activation of angiogenic pathways. Comparative transcriptomic analysis of human angiosarcomas and canine hemangiosarcomas identified shared molecular signatures associated with activation of PI3K/AKT/mTOR pathways. Our data suggest that genome instability induced by TP53 mutations might create a predisposition for fusion events that may contribute to tumor progression by promoting selection and/or enhancing fitness through activation of convergent angiogenic pathways in this vascular malignancy. IMPLICATIONS: This study shows that, while drive events of malignant vasoformative tumors of humans and dogs include diverse mutations and stochastic rearrangements that create novel fusion genes, convergent transcriptional programs govern the highly conserved morphologic organization and biological behavior of these tumors in both species. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33649193      PMCID: PMC8137578          DOI: 10.1158/1541-7786.MCR-20-0937

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  69 in total

Review 1.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

2.  Angiosarcoma: clinical and molecular insights.

Authors:  Guy Lahat; Asha R Dhuka; Hen Hallevi; Lianchun Xiao; Changye Zou; Kerrington D Smith; Thuy L Phung; Raphael E Pollock; Robert Benjamin; Kelly K Hunt; Alexander J Lazar; Dina Lev
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

3.  Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization.

Authors:  Brandi H Gorden; Jong-Hyuk Kim; Aaron L Sarver; Aric M Frantz; Matthew Breen; Kerstin Lindblad-Toh; Timothy D O'Brien; Leslie C Sharkey; Jaime F Modiano; Erin B Dickerson
Journal:  Am J Pathol       Date:  2014-02-11       Impact factor: 4.307

4.  Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens.

Authors:  P Rudolph; J Peters; D Lorenz; D Schmidt; R Parwaresch
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

5.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

6.  Inferring tumour purity and stromal and immune cell admixture from expression data.

Authors:  Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Recurrent PTPRB and PLCG1 mutations in angiosarcoma.

Authors:  Sam Behjati; Patrick S Tarpey; Helen Sheldon; Inigo Martincorena; Peter Van Loo; Gunes Gundem; David C Wedge; Manasa Ramakrishna; Susanna L Cooke; Nischalan Pillay; Hans Kristian M Vollan; Elli Papaemmanuil; Hans Koss; Tom D Bunney; Claire Hardy; Olivia R Joseph; Sancha Martin; Laura Mudie; Adam Butler; Jon W Teague; Meena Patil; Graham Steers; Yu Cao; Curtis Gumbs; Davis Ingram; Alexander J Lazar; Latasha Little; Harshad Mahadeshwar; Alexei Protopopov; Ghadah A Al Sannaa; Sahil Seth; Xingzhi Song; Jiabin Tang; Jianhua Zhang; Vinod Ravi; Keila E Torres; Bhavisha Khatri; Dina Halai; Ioannis Roxanis; Daniel Baumhoer; Roberto Tirabosco; M Fernanda Amary; Chris Boshoff; Ultan McDermott; Matilda Katan; Michael R Stratton; P Andrew Futreal; Adrienne M Flanagan; Adrian Harris; Peter J Campbell
Journal:  Nat Genet       Date:  2014-03-16       Impact factor: 38.330

8.  The landscape of kinase fusions in cancer.

Authors:  Nicolas Stransky; Ethan Cerami; Stefanie Schalm; Joseph L Kim; Christoph Lengauer
Journal:  Nat Commun       Date:  2014-09-10       Impact factor: 14.919

Review 9.  Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives.

Authors:  Jong-Hyuk Kim; Ashley J Graef; Erin B Dickerson; Jaime F Modiano
Journal:  Vet Sci       Date:  2015-11-06

10.  Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.

Authors:  Guannan Wang; Ming Wu; Amy C Durham; Enrico Radaelli; Nicola J Mason; XiaoWei Xu; David B Roth
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

View more
  3 in total

1.  Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients.

Authors:  Shukmei Wong; E J Ehrhart; Samuel Stewart; Victoria Zismann; Jacob Cawley; Rebecca Halperin; Natalia Briones; Keith Richter; Karthigayini Sivaprakasam; Nieves Perdigones; Tania Contente-Cuomo; Salvatore Facista; Jeffrey M Trent; Muhammed Murtaza; Chand Khanna; William P D Hendricks
Journal:  PLoS One       Date:  2022-07-22       Impact factor: 3.752

2.  Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report.

Authors:  Lin Huang; Changlong Qin; Dan Pu; Yanyang Liu; Massimiliano Bassi; Lukas Käsmann; Lu Li
Journal:  Transl Lung Cancer Res       Date:  2022-08

3.  Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2-Cre mice.

Authors:  Jason A Hanna; Casey G Langdon; Matthew R Garcia; Annaleigh Benton; Nadia A Lanman; David Finkelstein; Jerold E Rehg; Mark E Hatley
Journal:  J Pathol       Date:  2022-02-15       Impact factor: 9.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.